Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/902482/000095013406015037/f22390e10vq.htm
EXHIBIT 99.1
COMPANY CONTACT:
|
INVESTOR CONTACTS: | |
Mark Fischer-Colbrie
|
Jody Cain (jcain@lhai.com) | |
Chief Financial Officer
|
Bruce Voss (bvoss@lhai.com) | |
Adeza Biomedical Corporation
|
Lippert/Heilshorn & Associates, Inc. | |
(408) 745-0975 ext 520
|
(310) 691-7100 | |
ir@adeza.com |
ADEZA ANNOUNCES 2006 SECOND QUARTER FINANCIAL RESULTS
Achieves
16th Consecutive Quarter of Profitability on Record Product Sales
Company Affirms 2006 Revenue Guidance
Company Affirms 2006 Revenue Guidance
Conference Call to Begin at 4:30 p.m. Eastern Time Today
SUNNYVALE, Calif. (August 3, 2006) — Adeza (NASDAQ: ADZA) today announced financial results for
the second quarter ended June 30, 2006.
Adeza reported record product sales of $13.0 million for the second quarter of 2006, an increase of
23% from product sales of $10.6 million for the second quarter of 2005. This increase was due to
higher sales volume of FullTerm™, The Fetal Fibronectin Test.
Net income for the second quarter of 2006 was $537,000, or diluted earnings per share of $0.03,
which included charges of $931,000 for stock-based compensation expense. Net income for the second
quarter of 2005 was $1.8 million, or diluted earnings per share of $0.10, which included no
stock-based compensation expense related to SFAS 123R and a 5% tax rate.
Gross profit for the second quarter of 2006 was $11.1 million, or 85.4%, and included stock-based
compensation expense of $48,000. This compares with gross profit of $9.2 million, or 86.6%, for
the second quarter of 2005.
Sales and marketing expenses for the second quarter of 2006 were $7.4 million, including
stock-based compensation expense of $457,000, compared with $4.8 million for the same quarter in
2005. This increase reflects expansion of the company’s direct sales force and marketing programs.
General and administrative expenses for the second quarter of 2006 were $2.2 million, including
stock-based compensation expense of $352,000, compared with $1.9 million in the comparable quarter
of the prior year. Research and development expenses were $1.6 million for the second quarter of
2006, including stock-based compensation expense of $75,000, compared with $1.2 million in the same
quarter of the prior year. This increase was mainly due to product development efforts, including
costs related to Gestiva™, Adeza’s drug candidate for the prevention of preterm birth in women with
a history of preterm delivery.
Product sales for the first half of 2006 totaled $23.8 million, an increase of 18% from $20.2
million for the first half of 2005. For the six months ended June 30, 2006 Adeza reported net
income of $543,000, or diluted earnings per share of $0.03, which included $1.8 million for
stock-based compensation expense due to the adoption of SFAS 123R. This compares with net income
of $3.3 million, or diluted earnings per share of $0.18, for the
six months ended June 30, 2005, which included no employee
stock-based compensation expense related to SFAS 123R and a 5% tax
rate.
As of June 30, 2006 Adeza had cash and cash equivalents of $93.4 million, an increase of $2.8
million from $90.5 million of cash and cash equivalents as of March 31, 2006 and an increase of
$3.6 million since December 31, 2005. Stockholders’ equity was $100.2 million and working capital
was $99.5 million as of June 30, 2006.
The following information was filed by Adeza Biomedical Corp on Thursday, August 3, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Adeza Biomedical Corp's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Adeza Biomedical Corp.
902482 Quarterly Reports
- 10-Q Quarterly Report November 2006
-
10-Q Quarterly Report August 2006
- 10-Q Quarterly Report May 2006
- 10-Q Quarterly Report November 2005
- 10-Q Quarterly Report August 2005
